Cleo Diagnostics Ltd has released a press release.
Appendix 4E and 2024 Annual Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Earlier from CLEO Diagnostics
- CLEO Selects U.S. Clinical Trial Sites
- Cleo Commences US Regulatory Process with FDA
- COV Ovarian Cancer Blood Test Outperforms Clinical Benchmark
- COV Appoints CRO to Manage US Ovarian Cancer Clinical Trials
- CLEO Appoints Partner to Commence U.S. Market Access Program
Later from CLEO Diagnostics
- Cleo Commences U.S. Clinical Trials
- The Royal Women's Hospital Joins CLEO Ovarian Cancer Trial
- CLEO Further Expands Ovarian Cancer Trial with Siles Health
- Price Query Response
- CLEO Delivers Commercial Development Milestone
Follow CLEO Diagnostics into a list and get an email when it puts out news.
Follow CLEO Diagnostics